ArticleNPJ precision oncology2026
MEK inhibition in adult patients with pilocytic astrocytomas.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and safety of proton radiotherapy for progressive or surgically unfavorable adult pilocytic astrocytoma: a single-center experience.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pilocytic astrocytomas (PAs) are rare primary brain tumors in adults and exhibit worse outcomes compared with pediatric cases. Surgery is the primary therapeutic approach, whereas radiation therapy (RT) is reserved for symptomatic recurrence but is associated with substantial long-term toxicity. PAs are characterized by the activation of the mitogen-activated protein kinase (MAPK) signaling pathway and Mitogen-activated protein kinase kinase (MEK) inhibitors have demonstrated effectivity in pediatric populations, though data in adults remain limited. We retrospectively analyzed data of five adult patients (ages 30-79), four with PAs and one with PA with anaplastic transformation, that were administered trametinib, a MEK1/2 inhibitor. All tumors harbored somatic NF-1 mutations, with one germline NF-1 case. According to RANO 2.0 criteria, three patients achieved partial responses and two had stable disease, with neurological improvement in two cases. Median progression-free survival was 16.65 months, supporting MEK inhibition as an effective treatment strategy in adult PAs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.